Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
- Conditions
- First Posted Date
- 2003-03-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 274
- Registration Number
- NCT00055562
- Locations
- ๐บ๐ธ
UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States
๐จ๐ฆPrincess Margaret Hospital, Toronto, Ontario, Canada
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-07
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00051116
- Locations
- ๐บ๐ธ
Myeloma Institute University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 220
- Registration Number
- NCT00050843
- Locations
- ๐บ๐ธ
Beaumont Cancer Center, Royal Oak, Michigan, United States
๐บ๐ธTexas Oncology PA-BMT Center, Dallas, Texas, United States
๐บ๐ธNorthwest Medical Specialists, Arlington Heights, Illinois, United States
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
- First Posted Date
- 2002-10-09
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT00047476
- Locations
- ๐บ๐ธ
Clinical Trials and Research Associates, Montebello, California, United States
๐บ๐ธCancer Research Network Inc, Plantation, Florida, United States
๐บ๐ธCalifornia Cancer Care Inc, Greenbrae, California, United States
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2006-07-13
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 460
- Registration Number
- NCT00046527
- Locations
- ๐บ๐ธ
Abraxis Bioscience, Inc, Durham, North Carolina, United States
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00046514
- Locations
- ๐บ๐ธ
Abraxis BioScience, Inc., Raleigh, North Carolina, United States
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
- Conditions
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT00046423
- Locations
- ๐บ๐ธ
Abraxis Bioscience, Inc., Durham, North Carolina, United States
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT00046735
- Locations
- ๐บ๐ธ
Wake Forest University, Winston-Salem, North Carolina, United States
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
- First Posted Date
- 2002-09-11
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT00045786
- Locations
- ๐บ๐ธ
Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois, United States
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2002-08-29
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 25
- Registration Number
- NCT00044382
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States